Search

Your search keyword '"Długosz-Danecka, Monika"' showing total 183 results
Start Over Author "Długosz-Danecka, Monika"
183 results on '"Długosz-Danecka, Monika"'

2. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Author

Straus, David J, Długosz-Danecka, Monika, Connors, Joseph M, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J, Bartlett, Nancy L, Walewski, Jan, Ramchandren, Radhakrishnan, Zinzani, Pier Luigi, Hutchings, Martin, Munoz, Javier, Lee, Hun Ju, Kim, Won Seog, Advani, Ranjana, Ansell, Stephen M, Younes, Anas, Gallamini, Andrea, Liu, Rachael, Little, Meredith, Fenton, Keenan, Fanale, Michelle, and Radford, John

Published
2021
Full Text
View/download PDF

3. Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors

Author

Puła, Bartosz, Długosz-Danecka, Monika, Salomon-Perzyński, Aleksander, Szymczyk, Agnieszka, Subocz, Edyta, Budziszewska, Bożena Katarzyna, Rybka, Justyna, Gil, Lidia, Waszczuk-Gajda, Anna, Iskierka-Jażdżewska, Elżbieta, Zaucha, Jan M., Osowiecki, Michał, Piszczek, Weronika, Steckiewicz, Paweł, Szukalski, Łukasz, Hus, Marek, Lech-Marańda, Ewa, Jurczak, Wojciech, and Jamroziak, Krzysztof

Published
2020
Full Text
View/download PDF

4. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Author

Straus, David J., Długosz-Danecka, Monika, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Walewski, Jan, Ramchandren, Radhakrishnan, Zinzani, Pier Luigi, Hutchings, Martin, Connors, Joseph M., Radford, John, Munoz, Javier, Kim, Won Seog, Advani, Ranjana, Ansell, Stephen M., Younes, Anas, Miao, Harry, Liu, Rachael, Fenton, Keenan, Forero-Torres, Andres, and Gallamini, Andrea

Published
2020
Full Text
View/download PDF

5. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Author

Le Gouill, Steven, Długosz-Danecka, Monika, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Smith, Stephen D., Doorduijn, Jeanette K., Panizo, Carlos, Shah, Bijal D., Davies, Andrew J., Eek, Richard, Jacobsen, Eric, Kater, Arnon P., Robak, Tadeusz, Jain, Preetesh, Calvo, Roser, Tao, Lin, Wang, Michael, Le Gouill, Steven, Długosz-Danecka, Monika, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Smith, Stephen D., Doorduijn, Jeanette K., Panizo, Carlos, Shah, Bijal D., Davies, Andrew J., Eek, Richard, Jacobsen, Eric, Kater, Arnon P., Robak, Tadeusz, Jain, Preetesh, Calvo, Roser, Tao, Lin, and Wang, Michael

Published
2024

8. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Author

Wang, Michael, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Casasnovas, Olivier, Smith, Stephen D., Damaj, Gandhi, Doorduijn, Jeanette K., Lamy, Thierry, Morschhauser, Franck, Panizo, Carlos, Shah, Bijal, Davies, Andrew, Eek, Richard, Dupuis, Jehan, Jacobsen, Eric, Kater, Arnon P., Le Gouill, Steven, Oberic, Lucie, Robak, Tadeusz, Jain, Preetesh, Frigault, Melanie M., Izumi, Raquel, Nguyen, Dorothy, Patel, Priti, Yin, Ming, and Długosz-Danecka, Monika

Published
2019
Full Text
View/download PDF

9. Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders

Author

Szmit, Sebastian, Jurczak, Wojciech, Zaucha, Jan Maciej, Długosz-Danecka, Monika, Sosnowska-Pasiarska, Barbara, Chmielowska, Ewa, Joks, Monika, Drozd-Sokołowska, Joanna, Knopińska-Posłuszny, Wanda, Spychałowicz, Wojciech, Kumiega, Beata, Charliński, Grzegorz, Morawska, Marta, and Słomian, Grzegorz

Published
2017
Full Text
View/download PDF

10. A practical approach to the ESC 2022 cardio-oncology guidelines. Comments by a team of experts: cardiologists and oncologists

Author

Leszek, Przemysław, primary, Klotzka, Aneta, additional, Bartuś, Stanisław, additional, Burchardt, Paweł, additional, Czarnecka, Anna M, additional, Długosz-Danecka, Monika, additional, Gierlotka, Marek, additional, Koseła-Paterczyk, Hanna, additional, Krawczyk-Ożóg, Agata, additional, Kubiatowski, Tomasz, additional, Kurzyna, Marcin, additional, Maciejczyk, Adam, additional, Mitkowski, Przemysław, additional, Prejbisz, Aleksander, additional, Rutkowski, Piotr, additional, Sierko, Ewa, additional, Sterliński, Maciej, additional, Szmit, Sebastian, additional, Szwiec, Marek, additional, Tajstra, Mateusz, additional, Tycińska, Agnieszka, additional, Witkowski, Adam, additional, Wojakowski, Wojciech, additional, and Cybulska-Stopa, Bożena, additional

Published
2023
Full Text
View/download PDF

11. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Author

Le Gouill, Steven, primary, Długosz-Danecka, Monika, additional, Rule, Simon, additional, Zinzani, Pier Luigi, additional, Goy, Andre, additional, Smith, Stephen D., additional, Doorduijn, Jeanette K., additional, Panizo, Carlos, additional, Shah, Bijal D., additional, Davies, Andrew J., additional, Eek, Richard, additional, Jacobsen, Eric, additional, Kater, Arnon P., additional, Robak, Tadeusz, additional, Jain, Preetesh, additional, Calvo, Roser, additional, Tao, Lin, additional, and Wang, Michael, additional

Published
2023
Full Text
View/download PDF

13. Molnupiravir is effective in patients with haematological malignancies

Author

Bołkun, Łukasz, primary, Pula, Bartosz, additional, Kołkowska‐Leśniak, Agnieszka, additional, Morawska, Marta, additional, Cichocka, Edyta, additional, Charlinski, Grzegorz, additional, Garus, Bartosz, additional, Giebel, Sebastian, additional, Piszcz, Jaroslaw, additional, Drozd‐Sokolowska, Joanna, additional, Kwiatkowski, Jacek, additional, Biernat, Monika, additional, Hus, Iwona, additional, Lech‐Maranda, Ewa, additional, Długosz‐Danecka, Monika, additional, Giannopoulos, Krzysztof, additional, and Wróbel, Tomasz, additional

Published
2023
Full Text
View/download PDF

16. A practical approach to the 2022 ESC cardio-oncology guidelines: Comments by a team of experts - cardiologists and oncologists.

Author

Leszek, Przemysław, Klotzka, Aneta, Bartuś, Stanisław, Burchardt, Paweł, Czarnecka, Anna M., Długosz-Danecka, Monika, Gierlotka, Marek, Koseła-Paterczyk, Hanna, Krawczyk-Ożóg, Agata, Kubiatowski, Tomasz, Kurzyna, Marcin, Maciejczyk, Adam, Mitkowski, Przemysław, Prejbisz, Aleksander, Rutkowski, Piotr, Sierko, Ewa, Sterliński, Maciej, Szmit, Sebastian, Szwiec, Marek, and Tajstra, Mateusz

Published
2023
Full Text
View/download PDF

17. Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia—A Multicenter Report by the Polish Lymphoma Research Group

Author

Drozd-Sokołowska, Joanna, primary, Waszczuk-Gajda, Anna, additional, Witkowska, Magdalena, additional, Sienkiewicz, Elżbieta, additional, Kopińska, Anna, additional, Kołkowska-Leśniak, Agnieszka, additional, Barankiewicz, Joanna, additional, Długosz-Danecka, Monika, additional, Smolewski, Piotr, additional, Helbig, Grzegorz, additional, Lech-Marańda, Ewa, additional, Jurczak, Wojciech, additional, Biecek, Przemysław, additional, Giebel, Sebastian, additional, Wiktor-Jędrzejczak, Wiesław, additional, and Basak, Grzegorz, additional

Published
2022
Full Text
View/download PDF

18. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

Author

Ansell, Stephen M., primary, Radford, John, additional, Connors, Joseph M., additional, Długosz-Danecka, Monika, additional, Kim, Won-Seog, additional, Gallamini, Andrea, additional, Ramchandren, Radhakrishnan, additional, Friedberg, Jonathan W., additional, Advani, Ranjana, additional, Hutchings, Martin, additional, Evens, Andrew M., additional, Smolewski, Piotr, additional, Savage, Kerry J., additional, Bartlett, Nancy L., additional, Eom, Hyeon-Seok, additional, Abramson, Jeremy S., additional, Dong, Cassie, additional, Campana, Frank, additional, Fenton, Keenan, additional, Puhlmann, Markus, additional, and Straus, David J., additional

Published
2022
Full Text
View/download PDF

20. Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia

Author

Puła, Bartosz, primary, Pruszczyk, Katarzyna, additional, Pietrusza, Ewa, additional, Morawska, Marta, additional, Piszczek, Weronika, additional, Kalicińska, Elżbieta, additional, Szeremet, Agnieszka, additional, Tryc-Szponder, Jagoda, additional, Wąsik-Szczepanek, Ewa, additional, Drozd-Sokołowska, Joanna, additional, Krzemień, Helena, additional, Rejus, Aleksandra, additional, Gajewska, Małgorzata, additional, Wiśniewski, Kamil, additional, Wysocki, Maciej, additional, Majeranowski, Alan, additional, Paszkiewicz-Kozik, Ewa, additional, Steckiewicz, Paweł, additional, Szukalski, Łukasz, additional, Bołkun, Łukasz, additional, Długosz-Danecka, Monika, additional, Giannopoulos, Krzysztof, additional, Jamroziak, Krzysztof, additional, Lech-Marańda, Ewa, additional, and Hus, Iwona, additional

Published
2022
Full Text
View/download PDF

21. Poster: HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Author

Ramchandren, Radhakrishnan, primary, Długosz-Danecka, Monika, additional, Connors, Joseph M., additional, Radford, John, additional, Illés, Árpád, additional, Picardi, Marco, additional, Lech-Maranda, Ewa, additional, Feldman, Tatyana, additional, Smolewski, Piotr, additional, Savage, Kerry J., additional, Bartlett, Nancy L., additional, Walewski, Jan, additional, Zinzani, Pier Luigi, additional, Hutchings, Martin, additional, Munoz, Javier, additional, Kim, Won Seog, additional, Advani, Ranjana, additional, Ansell, Stephen M., additional, Gallamini, Andrea, additional, Alekseev, Sergey, additional, Lee, Hun Ju, additional, Liu, Rachael, additional, Little, Meredith, additional, Fenton, Keenan, additional, Fanale, Michelle, additional, and Straus, David J., additional

Published
2021
Full Text
View/download PDF

22. Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Author

Straus, David J., Dlugosz-Danecka, Monika, Connors, Joseph M., Illés, Árpád, Picardi, Marco, Lech-Marańda, Ewa, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Walewski, Jan, Ramchandren, Radhakrishnan, Zinzani, Pier Luigi, Hutchings, Martin, Munoz, Javier, Kim, Won Seog, Advani, Ranjana, Ansell, Stephen M., Younes, Anas, Gallamini, Andrea, Liu, Rachael, Little, Meredith, Fenton, Keenan, Fanale, Michelle A., and Radford, John A.

Published
2020
Full Text
View/download PDF

23. Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Author

Gribben, John G., Jurczak, Wojciech, Jacobs, Ryan W., Grosicki, Sebastian, Giannopoulos, Krzysztof, Wrobel, Tomasz, Zafar, Syed F., Cultrera, Jennifer L., Kambhampati, Suman, Danilov, Alexey, Burke, John M., Goldschmidt, Jerome, Beach, Douglas F., Huntington, Scott F., Pinilla Ibarz, Javier, Sharman, Jeff P, Siddiqi, Tanya, Brander, Danielle M., Pagel, John M., Kolibaba, Kathryn S., Dlugosz-Danecka, Monika, Ghosh, Nilanjan, Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A., Weiss, Michael S., and Flinn, Ian W.

Published
2020
Full Text
View/download PDF

26. The Outcome of the First-Line Therapy of Patients with Follicular Lymphoma during COVID-19 Pandemic. a Real-World Data from the Polish Lymphoma Research Group (PLRG)

Author

Paszkiewicz-Kozik, Ewa, Palka, Monika, Debowska, Malgorzata, Szymanski, Marcin, Konska, Agnieszka, Kalicinska, Elzbieta, Tyczynska, Agata, Drozd-Sokolowska, Joanna, Giza, Agnieszka, Swoboda, Ryszard, Dabrowska-Iwanicka, Anna Paulina, Morawska, Marta, Owczarek-Kaczmarek, Justyna, Bolkun, Lukasz, Kopinska, Anna, Wasik-Szczepanek, Ewa, Maksylewicz, Dominika, Wisniewska, Anna, Targonski, Lukasz, Subocz, Edyta, Steckiewicz, Pawel, Domanska-Czyz, Katarzyna, Ostrowska, Beata, Swierkowska, Monika, Krzanowski, Jacek, Druzd-Sitek, Agnieszka, Mroz-Zycinska, Ewa, Romejko-Jarosinska, Joanna, Hus, Iwona, Dlugosz-Danecka, Monika, Lech-Maranda, Ewa, Wrobel, Tomasz, Zaucha, Jan M., and Walewski, Jan

Published
2023
Full Text
View/download PDF

27. Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies.

Author

Cheah, Chan, primary, Jurczak, Wojciech, additional, Lasica, Masa, additional, Wickham, Nicholas W., additional, Wrobel, Tomasz, additional, Walewski, Jan Andrzej, additional, Yannakou, Costas K., additional, Cheung, Stanley, additional, Lewis, Katharine L., additional, Długosz-Danecka, Monika, additional, Giannopoulos, Krzysztof, additional, Miskin, Hari P., additional, Tang, Jian-Ping, additional, Normant, Emmanuel, additional, O'Connor, Owen A., additional, Ricart, Alejandro Daniel, additional, and Tam, Constantine Si Lun, additional

Published
2021
Full Text
View/download PDF

31. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Author

Goldman-Mazur, Sarah, primary, Jurczyszyn, Artur, additional, Castillo, Jorge J., additional, Waszczuk-Gajda, Anna, additional, Grząśko, Norbert, additional, Radocha, Jakub, additional, Bittrich, Max, additional, Kortüm, Klaus Martin, additional, Gozzetti, Alessandro, additional, Usnarska-Zubkiewicz, Lidia, additional, Valls, Julio D., additional, Jayabalan, David S., additional, Niesvizky, Ruben, additional, Kelman, Julia, additional, Coriu, Daniel, additional, Rosiñol, Laura, additional, Szukalski, Łukasz, additional, González-Calle, Veronica, additional, Mateos, María-Victoria, additional, Jamroziak, Krzysztof, additional, Hus, Iwona, additional, Avivi, Irit, additional, Cohen, Yael, additional, Mazur, Piotr, additional, Suska, Anna, additional, Chappell, Aimee, additional, Madduri, Deepu, additional, Chhabra, Saurabh, additional, Kleman, Ariel, additional, Hari, Parameswaran, additional, Delforge, Michel, additional, Robak, Paweł, additional, Gentile, Massimo, additional, Kozłowska, Izabela, additional, Goldberg, Stuart L., additional, Czepiel, Jacek, additional, Długosz-Danecka, Monika, additional, Silbermann, Rebecca, additional, Olszewski, Adam J., additional, Barth, Peter, additional, Mikala, Gabor, additional, Chim, Chor S., additional, and Vesole, David H., additional

Published
2020
Full Text
View/download PDF

32. Early chemotherapy de-escalation strategy in patients with advanced-stage Hodgkin lymphoma with negative positron emission tomography scan after 2 escalated BEACOPP cycles

Author

Długosz-Danecka, Monika, Szmit, Sebastian, Kocurek, Anna, Koźlik, Paweł, Giza, Agnieszka, Zimowska-Curyło, Dagmara, Małkowski, Bogdan, Sowa-Staszczak, Anna, Kużdżał, Jarosław, and Jurczak, Wojciech

Subjects
de‑escalation, positron emission tomography, toxicity, BEACOPP, Hodgkin lymphoma
Abstract

Escalated BEACOPP (escBEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) significantly improves overall response rates (ORRs) and prolongs progression‑free survival (PFS) in patients with advanced‑stage Hodgkin lymphoma (HL). However, 6 to 8 cycles of escBEACOPP are associated with increased acute toxicity and late complications. We aimed to determine the role of early positron emission tomography-computed tomography (PET‑CT) response assessment in a de‑escalation strategy. We retrospectively analyzed 188 consecutive patients with advanced‑stage HL treated at diagnosis. Patients received 2 cycles of escBEACOPP followed by an early PET‑CT response assessment performed after 2 cycles of chemotherapy (PET2). Patients with an active disease continued therapy with escBEACOPP, while those with negative PET2 were de‑escalated to ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). Radiotherapy was allowed in patients with stage IIBX. PET2 allowed for de‑escalation of therapy in 141 patients (75%). Their ORR was 92.2%, with a complete remission (CR) rate of 91.5%; 10‑year PFS and overall survival (OS) were 87.2% and 95%, respectively. In the whole cohort, ORR was 87.8% (CR, 85.6%), while the 10‑year PFS and OS were 79.3% and 89.4%, respectively. Hematological and thromboembolic complications were significantly more frequent in patients treated with 6 escBEACOPP cycles, including febrile neutropenia (25 patients, [53.2%] vs 7 [5%]), serious anemia (35 [74.5%] vs 11 [7.8%]), or thrombocytopenia (16 [34%] vs 7 [5%]) (P

Published
2019

34. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

Author

Goldman‐Mazur, Sarah, primary, Jurczyszyn, Artur, additional, Castillo, Jorge J., additional, Waszczuk‐Gajda, Anna, additional, Grząśko, Norbert, additional, Radocha, Jakub, additional, Bittrich, Max, additional, Kortüm, K. Martin, additional, Gozzetti, Alessandro, additional, Usnarska‐Zubkiewicz, Lidia, additional, Davila Valls, Julio, additional, Jayabalan, David S., additional, Niesvizky, Ruben, additional, Kelman, Julia, additional, Coriu, Daniel, additional, Rosiñol, Laura, additional, Szukalski, Łukasz, additional, González‐Calle, Veronica, additional, Mateos, Maria V., additional, Jamroziak, Krzysztof, additional, Hus, Iwona, additional, Avivi, Irit, additional, Cohen, Yael, additional, Suska, Anna, additional, Chappell, Aimee, additional, Madduri, Deepu, additional, Chhabra, Saurabh, additional, Kleman, Ariel, additional, Hari, Parameswaran, additional, Delforge, Michel, additional, Robak, Paweł, additional, Gentile, Massimo, additional, Kozłowska, Izabela, additional, Goldberg, Stuart L., additional, Czepiel, Jacek, additional, Silbermann, Rebecca, additional, Olszewski, Adam J., additional, Barth, Peter, additional, Mikala, Gabor, additional, Chim, Chor S., additional, Długosz‐Danecka, Monika, additional, Grosicki, Sebastian, additional, and Vesole, David H., additional

Published
2020
Full Text
View/download PDF

35. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B‐cell non‐Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)

Author

Pettengell, Ruth, primary, Długosz‐Danecka, Monika, additional, Andorsky, David, additional, Belada, David, additional, Georgiev, Pencho, additional, Quick, Donald, additional, Singer, Jack W., additional, Singh, Simran B., additional, Pallis, Athanasios, additional, Egorov, Anton, additional, and Salles, Gilles, additional

Published
2019
Full Text
View/download PDF

36. Outcomes of treatment with dose‐adjusted EPOCH‐R or R‐CHOP in primary mediastinal large B‐cell lymphoma

Author

Malenda, Agata, primary, Kołkowska‐Leśniak, Agnieszka, additional, Puła, Bartosz, additional, Długosz‐Danecka, Monika, additional, Chełstowska, Monika, additional, Końska, Agnieszka, additional, Giza, Agnieszka, additional, Lech‐Marańda, Ewa, additional, Jurczak, Wojciech, additional, and Warzocha, Krzysztof, additional

Published
2019
Full Text
View/download PDF

39. High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group

Author

Hus, Iwona, primary, Mańko, Joanna, additional, Jawniak, Dariusz, additional, Jurczyszyn, Artur, additional, Charliński, Grzegorz, additional, Poniewierska‑Jasak, Katarzyna, additional, Usnarska‑Zubkiewicz, Lidia, additional, Sawicki, Mateusz, additional, Druzd‑Sitek, Agnieszka, additional, Świderska, Alina, additional, Kopińska, Anna, additional, Grząśko, Norbert, additional, Raźny, Małgorzata, additional, Wędłowska, Aleksandra, additional, Perzyński, Aleksander, additional, Gałązka, Aleksandra, additional, Dytfeld, Dominik, additional, Kubicki, Tadeusz, additional, Rodzaj, Marek, additional, Waszczuk‑Gajda, Anna, additional, Drozd‑Sokołowska, Joanna, additional, Pogł�dek, Bartłomiej, additional, Pasternak, Anna, additional, Długosz‑Danecka, Monika, additional, Szymczyk, Agnieszka, additional, and Dmoszyńska, Anna, additional

Published
2019
Full Text
View/download PDF

40. Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.

Author

Straus, David J., primary, Długosz-Danecka, Monika, additional, Alekseev, Sergiy, additional, Illés, Árpád, additional, Picardi, Marco, additional, Lech-Maranda, Ewa, additional, Feldman, Tatyana, additional, Savage, Kerry J., additional, Smolewski, Piotr, additional, Bartlett, Nancy L., additional, Gallamini, Andrea, additional, Walewski, Jan Andrzej, additional, Ramchandren, Rod, additional, Zinzani, Pier Luigi, additional, Connors, Joseph M., additional, Jolin, Hina, additional, Liu, Rachael, additional, Fenton, Keenan, additional, Fanale, Michelle, additional, and Radford, John A., additional

Published
2019
Full Text
View/download PDF

42. Early chemotherapy de-escalation strategy in advanced-stage Hodgkin lymphoma patients with negative positron emission tomography scan after two escalated BEACOPP cycles

Author

Długosz-Danecka, Monika, primary, Szmit, Sebastian, additional, Kocurek, Anna, additional, Koźlik, Paweł, additional, Giza, Agnieszka, additional, Zimowska-Curyło, Dagmara, additional, Małkowski, Bogdan, additional, Sowa-Staszczak, Anna, additional, Kużdżał, Jarosław, additional, and Jurczak, Wojciech, additional

Published
2019
Full Text
View/download PDF

44. Safety and Early Efficacy of Obinutuzumab in Combination with Chemotherapy in Treatment Naive Patients with Follicular Lymphoma - Report of Polish Lymphoma Research Group (PLRG)

Author

Paszkiewicz-Kozik, Ewa, Hus, Iwona, Palka, Monika, Debowska, Malgorzata, Konska, Agnieszka, Kotarska, Martyna, Tyczynska, Agata, Joks, Monika, Twardosz, Maja, Giza, Agnieszka, Wasik-Szczepanek, Ewa, Kalicinska, Elzbieta, Wisniewska, Anna, Morawska, Marta, Romejko-Jarosinska, Joanna, Lewicka, Barbara, Targonski, Lukasz, Osowiecki, Michal, Poplawska, Lidia, Szymanski, Marcin, Kruczkowska-Taranowicz, Kamila, Drozd-Sokolowska, Joanna, Swoboda, Ryszard, Domanska-Czyz, Katarzyna, Ostrowska, Beata, Swierkowska, Monika, Dabrowska-Iwanicka, Anna Paulina, Druzd-Sitek, Agnieszka, Konecki, Robert, Borawska, Anna, Dlugosz-Danecka, Monika, Lech-Marańda, Ewa, and Walewski, Jan

Published
2021
Full Text
View/download PDF

45. Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Author

Jacobs, Ryan, Jurczak, Wojciech, Flinn, Ian W., Grosicki, Sebastian, Giannopoulos, Krzysztof, Wróbel, Tomasz, Zafar, Syed F., Cultrera, Jennifer L., Kambhampati, Suman, Danilov, Alexey V., Burke, John M., Goldschmidt, Jerome, Beach, Douglas F., Huntington, Scott F., Pinilla Ibarz, Javier, Sharman, Jeff P., Siddiqi, Tanya, Brander, Danielle M., Shadman, Mazyar, Pagel, John M., Dlugosz-Danecka, Monika, Ghosh, Nilanjan, Kolibaba, Kathryn S., Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A., Weiss, Michael S., and Gribben, John G.

Published
2021
Full Text
View/download PDF

47. Ibrutinib

Author

Długosz-Danecka, Monika

Published
2018

49. Low incidence of ibrutinib discontinuation in real-life experience

Author

Długosz-Danecka, Monika, Piotrowska, Magdalena, Jakóbczyk, Małgorzata, Stój, Anastazja, and Jurczak, Wojciech

Subjects
side effects, ibrutinib, przewlekła białaczka limfocytowa, zdarzenia niepożądane, chronic lymphocytic leukemia, inhibitor kinazy Brutona, Bruton tyrosine kinase inhibitor, ibrutynib
Published
2018

50. Efficacy and safety of obinutuzumab-chlorambucil combination in the frontline treatment of elderly patients with chronic lymphocytic leukemia and comorbidities : real‑life data from Polish Adult Leukemia Group (PALG) analysis

Author

Długosz-Danecka, Monika, Jurczak, Wojciech, Łątka-Cabała, Ewa, Morawska, Marta, Gawroński, Krzysztof, Wiśniewska, Anna, Dudziński, Marek, Wąsik-Szczepanek, Ewa, Chmielowska, Ewa, Łabędź, Anna, Wdowiak, Kamil, and Hus, Iwona

Subjects
obinutuzumab, Cumulative Illness Rating Scale, hemic and lymphatic diseases, chronic lymphocytic leukemia, comorbidities
Abstract

Fludarabine- or bendamustine‑based upfront immunochemotherapy is the current standard of care in fit patients with chronic lymphocytic leukemia (CLL). These regimens are poorly tolerated by patients with comorbidities, for whom the obinutuzumab-chlorambucil combination became the recommended first‑line treatment. We aimed to analyze real‑life experience with the obinutuzumab-chlorambucil combination as the frontline treatment in elderly and unfit patients. The retrospective analysis included 86 elderly patients (median age, 74 years) with CLL and a significant burden of comorbidities, treated with obinutuzumab-chlorambucil as the frontline regimen. All patients had a Cumulative Illness Rating Scale score greater than 6 and/or creatinine clearance of 30 to 69 ml/min. Overall response rate at 2 months after treatment completion was 95.3%, with complete remission (CR) rate of 43% and partial remission (PR) rate of 52.3%. Stable disease rate was 4.7%. Progressive disease was not observed after treatment completion. The median progression‑free survival (PFS) was not reached after a median follow‑up of 18 months; estimated PFS at 30 months was 62%. We observed 6 relapses (7%), 3 (3.5%) in patients obtaining CR, and 3 (3.5%) in those with PR after immunochemotherapy. The most frequent adverse events were neutropenia and infusion‑related reactions (IRRs). Grade-3 neutropenia occurred in 11.6% of patients, and grade-3 IRRs, in 2.3%. There were no adverse events of grade 4 or 5. Our data confirm that the obinutuzumab-chlorambucil combination is an effective and well‑tolerated regimen in untreated CLL patients with comorbidities.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results